The pulmonary route as a way to drug repositioning in COVID-19 therapy

dc.creatorSarcinelli, MIchelle Alvares
dc.creatorSilva, Thalita Martins da
dc.creatorSilva, Andressa Daniele Artico
dc.creatorPatricio, Beatriz Ferreira de Carvalho
dc.creatorPaiva, Flávia Costa Mendes de
dc.creatorLima, Raissa Santos de
dc.creatorSilva, Manuela Leal da
dc.creatorRocha, Helvécio Vinícius Antunes
dc.date2022-07-19T17:14:25Z
dc.date2022-07-19T17:14:25Z
dc.date2021
dc.date.accessioned2023-09-26T21:05:30Z
dc.date.available2023-09-26T21:05:30Z
dc.identifierSARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021.
dc.identifier1773-2247
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/53868
dc.identifier10.1016/j.jddst.2021.102430
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8869001
dc.descriptionSince January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
dc.descriptionIntroduction: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society’s routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. Objective: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. Method: A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. Results: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. Conclusion: Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectSARS-CoV-2
dc.subjectCoronavírus
dc.subjectFormulações pulmonares
dc.subjectAdministração de drogas pulmonares
dc.subjectReaproveitamento de drogas
dc.subjectSARS-CoV-2
dc.subjectCoronavirus
dc.subjectPulmonary formulations
dc.subjectPulmonary drug delivery
dc.subjectDrug repurposing
dc.titleThe pulmonary route as a way to drug repositioning in COVID-19 therapy
dc.typeArticle


Este ítem pertenece a la siguiente institución